Language selection

Search

Patent 1253798 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1253798
(21) Application Number: 1253798
(54) English Title: HOMOGENEOUS FLUORESCENCE IMMUNOASSAY USING AT LIGHT ABSORBING MATERIAL
(54) French Title: DOSAGE IMMUNOLOGIQUE PAR FLUORESCENCE AYANT RECOURS A UN MATERIAU ABSORBANT LA LUMIERE
Status: Term Expired - Post Grant
Bibliographic Data
(51) International Patent Classification (IPC):
  • G1N 33/58 (2006.01)
  • G1N 21/64 (2006.01)
  • G1N 33/533 (2006.01)
  • G1N 33/542 (2006.01)
(72) Inventors :
  • WAGNER, DANIEL B. (United States of America)
  • BAFFI, ROBERT A. (United States of America)
(73) Owners :
  • BECTON, DICKINSON AND COMPANY
(71) Applicants :
  • BECTON, DICKINSON AND COMPANY (United States of America)
(74) Agent: GOWLING WLG (CANADA) LLP
(74) Associate agent:
(45) Issued: 1989-05-09
(22) Filed Date: 1985-11-18
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
700,578 (United States of America) 1985-02-11

Abstracts

English Abstract


HOMOGENEOUS FLUORESCENCE IMMUNOASSAY USING
A LIGHT ABSORBING MATERIAL
ABSTRACT OF THE DISCLOSURE
A method for separation-free solid phase immuno-
assay of an analyte includes contacting an anti-
analyte attached to the surface of a solid support
with the analyte, a light absorbing material and a
fluorescent tracer for the analyte. The resulting
mixture is incubated. The method includes applying
excitation light to the mixture and time resolved
measurement of fluorescence emission from the tracer.
All excitation light and fluorescence emission are
absorbed by the light absorbing material except that
absorbed and emitted by the tracer bound to the
anti-analyte whereby the only fluorescence emission
detected is from the bound tracer. Since free
tracer in the fluid phase of the assay medium does
not emit fluorescence, separation of the bound and
free fractions is unnecessary. The invention in-
cludes a kit of materials useful in performing an
immunoassay in accordance with the method of the
invention.


Claims

Note: Claims are shown in the official language in which they were submitted.


-24-
WHAT IS CLAIMED IS:
1. A method for determining an unknown quantity of
an analyte present in a fluid comprising:
(a) preparing a mixture by contacting an anti-
analyte attached to the surface of a light trans-
mitting solid support with a fluid containing an
unknown quantity of an analyte, a tracer consisting
of a fluorescent dye conjugated to said analyte or
to a ligand specific for said analyte, and a light
absorbing material having an absorption band which
overlaps the absorption band of said tracer;
(b) incubating said mixture;
(c) applying to said mixture a pulse of excitation
light through said solid support, the intensity and
duration of said pulse being sufficient to cause the
absorption of a portion of said excitation light by
said tracer;
(d) detecting fluorescence emission from bound tracer,
said emission being of sufficiently long decay time
to be detected subsequent to completion of said light
pulse and subsequent to the decay of substantially
all light emission due to components of said mixture
other than said bound tracer; and
(e) determining the quantity of said analyte in said
fluid by comparing the magnitude of said fluorescence
emission with the magnitude of fluorescence emission
established for a known quantity of the analyte.
2. The method in accordance with claim 1 wherein
said analyte is selected from the group of analytes con-
sisting of an antigen, a hapten and an antibody, and said
anti-analyte is selected from the group of anti-analytes
consisting of an antigen and an antibody.

-25-
3. The method in accordance with claim 1 wherein
said tracer consists of said analyte having said fluo-
rescent dye attached thereto, and wherein said tracer
reacts specifically with said anti-analyte.
4. The method in accordance with claim 3 wherein a
limited amount of said anti-analyte is attached to said
support and said analyte and said tracer bind competi-
tively to said anti-analyte.
5. The method in accordance with claim 1 wherein
said tracer is selected from the group of tracers consis-
ting of an antigen, an antibody and a bound antigen-
antibody complex having said fluorescent dye attached there-
to and wherein said tracer reacts specifically with said
analyte.
6. The method in accordance with claim 5 wherein
substantially all of said analyte binds to said anti-
analyte and said tracer binds to said analyte.
7. The method in accordance with claim 1 wherein
said fluorescent dye is a lanthanide chelate.
8. The method in accordance with claim 7 wherein
said lanthanide chelate is incorporated into a polymeric
particle.
9. The method in accordance with claim 1 wherein
said fluid is serum.
10. The method in accordance with claim 1 wherein
said light absorbing material is an arylaminonaphthalene
sulfonic acid.

-26-
11. The method in accordance with claim 7 wherein
the intensity of said pulse is from about 1 X 1040 to
2 X 1040 photons.
12. The method in accordance with claim 7 wherein
the duration of said pulse is from about 1 to 10 µs.
13. The method in accordance with claim 7 wherein
said pulse has a wavelength of from about 280 to 375 nm.
14. The method in accordance with claim 7 wherein
said fluorescence emission has a wavelength of from about
580 to 630 nm.
15. The method in accordance with claim 7 wherein
said fluorescence emission has a decay time of from about
0.5 to 1.0 ms.
16. The method in accordance with claim 1 wherein
said fluorescence emission is measured between consecutive
pulses.
17. The method in accordance with claim 1 wherein
said fluorescence emission is measured between 0.5 and
0.75 ms after completion of a pulse.
18. The method in accordance with claim 1 wherein
said fluorescence emission is measured at an angle of
from 2 to 20 degrees from the direction of said pulse of
excitation light.
19. A method for determining an unknown quantity
of an analyte in a fluid comprising:
(a) preparing a mixture by contacting an anti-analyte
attached to the surface of a light transmitting solid

-27-
support with a fluid containing an unknown quantity
of an analyte, a tracer consisting of a conjugate
of a fluorescent dye with said analyte, and a light
absorbing material having an absorption band which
overlaps the absorption band of said tracer;
(b) allowing the elapse of a period of time suffi-
cient to cause binding of said analyte and said
tracer to said anti-analyte;
(c) applying excitation light to said mixture through
said solid support;
(d) detecting time resolved light emission from
bound tracer; and
(e) determining the quantity of said analyte in said
fluid by comparing the magnitude of said detected
light emission with the magnitude of light emission
established for a known quantity of said analyte.
20. A method for determining an unknown quantity of
analyte present in a serum sample comprising:
(a) preparing a mixture by contacting an anti-analyte
attached to the surface of a light transmitting solid
support wherein the quantity of anti-analyte binding
sites available is insufficient to bind all of an
analyte, with a serum sample containing an unknown
quantity of said analyte, an arylaminonaphthalene
sulfonic acid, and a tracer consisting of said analyte
having attached thereto a particle having incorporated
therein a lanthanide chelate label;
(b) incubating said mixture;
(c) applying to said mixture through said solid
support a pulse of excitation light of wavelength about
280 to 375 nm, said pulse having an intensity of
about 1 X 1040 to 2 X 104° photons and a duration of
about l to 10 µs;
(d) detecting fluorescence emission having a wave-
length of about 580 to 630 nm and a decay time of

-28-
about 0.5 to 1.0 ms from bound tracer, said emission
being measured between consecutive excitation pulses
at an angle of about 2 to 20 degrees from the direc-
tion of said pulse and about 0.50 to 0.75 ms after
completion of a pulse; and
(e) determining the quantity of said analyte in said
serum sample by comparing the magnitude of said
fluorescence emission with the magnitude of fluores-
cence emission detected when a mixture containing a
known quantity of said analyte is determined in
accordance with steps (a) to (e).
21. The method in accordance with claim 20 wherein
said particle is a polymeric particle.
22. The method in accordance with claim 20 wherein
said lanthanide chelate is a europium or terbium ion
chelated to a .beta.-diketone.
23. A method for determining an unknown quantity of
analyte present in a serum sample comprising:
(a) preparing a mixture by contacting an anti-analyte
attached to the surface of a light transmitting solid
support wherein the quantity of anti-analyte binding
sites available is sufficient to bind essentially
all of an analyte with a fluid containing an unknown
quantity of said analyte, an arylaminonaphthalene
sulfonic acid, and a tracer consisting of a ligand
specific for said analyte, said ligand having
attached thereto a particle having incorporated
therein a lanthanide chelate label;
(b) incubating said mixture:
(c) applying to said mixture, through said solid
support, a pulse of excitation light of wavelength
about 280 to 375 nm, said pulse having an intensity

-29-
of about 1 X 1040 to 2 X 1040 photons and a duration
of about 1 to 10 µs;
(d) detecting fluorescence emission having a wave-
length of about 580 to 630 nm and a decay time of
about 0.5 to 1.0 ms, said emission being measured
between consecutive excitation pulses at an angle
of about 2 to 20 degrees from the direction of said
pulse and about 0.5 to 0.75 ms after completion of
a pulse; and
(e) determining the quantity of said analyte in said
serum sample by comparing the magnitude of said
fluorescence emission with the magnitude of fluo-
rescence emission when a mixture containing a known
quantity of said analyte is determined in accordance
with steps (a) to (e).
24. The method in accordance with claim 23 wherein
said particle is a polymeric particle.
25. The method in accordance with claim 23 wherein
said ligand is selected from the group of ligands con-
sisting of an antigen, an antibody and a bound antigen-
antibody complex.
26. The method in accordance with claim 23 wherein
said lanthanide chelate is a europium or terbium ion
chelated to a .beta.-diketone.
27. A kit of materials for performing an assay for
an unknown quantity of an analyte in a fluid comprising a
light transmitting solid support having attached thereto
an anti-analyte specific to an analyte, a tracer consis-
ting of a fluorescent dye conjugated to said analyte or
to a ligand specific for said analyte and a light absorbing
material having an absorption band which overlaps the
absorption band of said tracer.

-30-
28. The kit in accordance with claim 27 further
comprising at least one analyte sample of known concentra-
tion.

Description

Note: Descriptions are shown in the official language in which they were submitted.


25379~3 P- 8~9
HOMOGENEO~S FLU~RESCENCE IMMUNCASSAY USING
A LIGHT ABSORBING MATERIAL
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to an immunoassay of an
analyte and materials used therein, and more particu-
larly relates to a method and materials for immuno-
assay which does not require separation of bound andfree fractions.
2 Description of the Prior Art
.
A variety of assay systems which are both rapid
and sensitive has been developed to determine the
concentration of a substance in a fluid. Immuno-
assays depend on the binding of an antigen or hapten
to a specific antibody and have been particularly
useful because they give high levels of specificity
and sensitivity. These assays generally employ one
of the above reagents in labeled form, the labeled
reagent often being referred to as the tracer.
Immunoassay procedures may be carried out in solution
or on a solid support and may be either heterogeneous
or homogeneous. Heterogeneous assays require a
separation of bound tracer from free (unbound)
tracer. Homogeneous assays do not require a separa-
tion step and thereby provide significant advantage
in speed, convenience and ease of automation over
heterogeneous assays.
Radioimmunoassay ~RIA) procedures use radioiso-
topes as labels, provide high levels of sensitivity
and reproducibility, and are amenable to automation
for rapid processing of larye numbers oÇ samples.
However, all RIA procedures re~uire a separation
''~

~L:2537~
. ~
P-849
--2--
step, since the parameter measured (nuclear decay)
cannot be controlled by changing assay conditions or
components. In addition, isotopes are costly,
have relatively short shelf lives, require expensive
and complex equipment, and extensive safety measures
for their handling and disposal must be followed.
Enzymes have also been used as labels in immuno-
assay. Enzymeimmunoassay (EIA) may be homogeneous
and does not require precautions against radioac-
tivity. Conjugation of an enzyme with a protein isusually straightforward, and the resulting protein-
enzyme conjugate is generally stable. However, EIA
depends on the reaction of the enæyme conju~ate with
a substrate to produce a color which is measured,
and thus requires the additional step of providing an
enzyme substrate. In addition, suficient time must
be allowed for color development and an expensive
spectrophotometer for measuring color change must be
provided.
Some of the above disadvantages associated with
RIA or EIA have been overcome by use of fluorochromes
as labels in immunoassay. Fluoroimmunoassay (FIA)
provides direct detection of the label and is readily
adaptable to homogeneous assay procedures. However,
known homogeneous FIA methods using organic fluoro-
chromes, such as fluorescein or rhodamine deriva-
tives, have not achieved the high sensitivity of RIA
or EIA, largely because of light scattering by
impurities suspended in the assay medium and by
backyround fluorescence emission ~rom other fluores-
cent materials present in the assay medium. Scat-
terln~ i5 par~icularl~ troubl~some with fluorochromes

~L25379~3
P-849
having a short (50 nm or less) Stoke's shift (the
difference between the wavelength of the absorption
and emission)O For example, the Stoke's shift of
fluorescein isothiocyanate in only 20-30 nm. Back-
ground fluorescence is particularly troublesome whenthe assay medium is serum. The sensitivity of an
assay in serum may be reduced up to one hundred fold
compared to an identical assay in buffer.
The development o time-resolved fluoroimmuno~
assay (TR-FIA) has contributed to overcoming these
problems. In this procedure, a fluorochrome label
with a relatively long fluorescence emission decay
time is excited with a pulse of light, and fluores-
cence emission from the label is measured after a
preselected delay. Background emission of short
decay time (generaLly less than 10 ns) essentially
ceases during the delay and thereby does not inter-
fere with measurement of the specific emission
from the label. TR-FIA is most effective when the
fluorescent label has a decay time of 100-1000 ns and
a long Stoke's shift (100 nm or greater).
A class of labels meeting the requirements of
TR-FIA is the lanthanide chelates. Lanthanide ions,
in particular ions of europium and terbium form
highly ~luorescent chelates of long Stoke's shift (up
to 250 nm) with organic ligands, in particular w~th
~-diketones. The ligand portion of the chelate
absorbs excitation light and transfers the absorbed
energy to the chelated metal ion. The metal ion
emits the energy as fluorescenc-e of exceptionally
long decay time (1 ms). A discussion of the use of
lanthanide chelates ln TR-FIA is given in Analytical
~LochemLstry, 137 335 (1984).

~37~
P-849
U.S. Patent No. 4,058,732 to Wieder discloses a
method and apparatus for use of lanthanide chelates
and time resolution in analytical fluorescent
spectroscopy.
U.S. Patent No. 4,283,382 to Frank et al. dis-
closes an improvement in TR-FIA in which a lanthanide
chelate label is incorporated into a polymeric bead
lattice to eliminate water-induced quenching of the
fluorescence emission of the label.
U.S. Patent No. 4,374,120 to Soini et al.
discloses increased stability of lanthanide chelates
achieved by a 1:1:1 chelate of lanthanide, ~-dike-
tone, and an aminopolycarboxylic acid analgue having
a functional group useful for binding the chelate to
a protein.
European Patent Application EP 0,064,484-A2
discloses a TR-FIA procedure in which the substance
to be determined is coupled to a lanthanide by an
aminocarboxylic acid analogue, and, after incubation,
the lanthanide is split from the substance to be
determined and chelated to a ~-diketone before
detection.
Although the above methods have improved FIA,
there is still a need for a FIA of high sensitivity
which can be carried out rapidly without requiring a
separation of bound and free fractions.
SUMM~RY OF THE INVENTION
One aspect of the present invention comprises a
method for 90lid phase immunoassay of an analyte
without separation oE bound and ~ree fractions~ ~n

S37~
P-849
--5--
anti-analyte attached to the surface of a solid
s~pport is contacted with a fluid containing the
analyte, a light absorbing material and a tracer for
the analyte having an attached label which absorbs
and emits light. After incubation of the assay
mixture, excitation light is applied and light
emission is measured by time resolution. The magni-
tude of light emission is compared with the magnitude
of l.ight emission measured when one or more known
quantities of analyte is assayed under essentially
identical conditions.
Thus the present invention provides a method for
determining an unknown quantity of an analyte present in
a fluid comprising preparing a mixture by contacting an
anti-analyte attached to the surface of a light trans-
mitting solid support with a fluid containing an unknown
quantity of an analyte, a tracer consisting of a fluores-
cent dye conjugated to said analyte or to a ligand specific
for said analyte, and a light absorbing material having an
absorption band which overlaps th~ absorption band of said
tracer; incubating said mixture; applying to said mixture
a pulse of excitation light through said solid support, the
intensity and duration of said pulse being sufficient to
cause the absorption of a portion of said excitation light by
said tracer; detecting fluorescence emission from bound
tracer, said emission being of sufficiently long decay time
to be detected subsequent to completion of said liyht pulse
and subsequent to the decay of substantially all light emission
due to components of said mixture other than said bound tracer;
and detexmining the quantity of said analyte in said fluid
by comparing the ma~nitude of said fluorescence emission with
the ma~nikud~ o~ fluorescence emission established fQr a
known c~,uantity ~f the ana.lyte.
,.~
~;

37
-5a-
In another aspect the invention provides a kit of
materials for performing an assay for an unknown quantity
of an analyte in a fluid comprising a light transmitting
solid support having attached thereto an anti-analyte speci-
fic to an analyte, a tracer consisting of a fluorescent
dye conjugated to said analyte or -to a ligand specific for
said analyte and a light absorbing material having an
absorption band which overlaps the absorption band of said
tracer.
In a preferred embodiment of the method of the
invention, the label is a fluorescent dye of rela-
tively long decay time and the light absorbing
material is a UV absorbing compound having an absorp-
tion band which overlaps the absorption band of the
tracer.
In a particularly preferred embodiment o~ the
method of the invention, the analyte is in a serum
sample, the light-absorbing material is an aryla-
minonaphthalene sulfonic acidv the tracer is a
lanthanide chelate incorporated into a polymeric
particle attached to the analyte, and the tracer and
the analyte compete for an insufficient number of
anti-analyte binding sites.
In another embodiment of the method of the
invention, substantially all of the analyte binds to
both the anti-analyte and the tracer in a sandwich
assay.
, ,

~2~;3~79~3
, P-849
In accordance with the method of the invention,
a solid phase TR-FIA is carried out which does not
require a separation of bound and unbound fractions
whereby operational simplicity, speed and convenience
of homogeneous assays is achieved. The label is
detected directly without an additional substrate or
incubation period to generate a detectable material.
The method of the invention provides a highly
sensitive homogeneous assay essentially free of
interfering emission from other fluorescent materials
whereby an analyte present in very low concentration
can be accurately determined. Because the procedure
is exceptionally facile to carry out, it is readily
adaptable to automation.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a tube and other components of
use in a competitive immunoassay in accordance with
the method of the invention;
Figure 2 is a standard curve of an assay for
digoxin in accordance with the method of the inven-
tion; and
Figure 3 is a standard curve of an assay forhuman chorionic ganadotropin (HCG) in accordance with
the method of the invention.
DETAILED DESCRIPTION OF THE INVENTION
While this invention is sa~is~ied by embodiments
~s in many di~ferent ~orms, there will herein be de-
scrlbed in de~all preEerred embodimen~s oE the

-` 3L2S;~
P-849
invention, with the understanding that the present
disclosure is to be considered as exemplary of the
principles of the invention and is not intended to
limit the invention to the embodiments illustrated.
The scope of the invention will be measured by the
appended claims and their e~uivalents.
In accordance with the method of the invention,
the concentration of a substance present in a fluid
may be determined by means of an immunological
reaction. The substance, hereinafter referred to as
the analyte, may be an antigen, a hapten, or an
antibody, and may be present in any suitable fluid.
For example, the fluid may be a buffer, saline, or
a body fluid such as serum or urine. In some casesj
the analyte may be isolated from a body fluid and
subsequently be introduced into a different fluid,
such as buf~er, for determination.
By the term "immunological reaction," as used
herein, is meant a specific binding reaction of an
antigen and an antibody, a hapten and an antibody, or
any appropriate analogue o~ an antigen, an antibody,
or a hapten which also binds specifically.
The immunological reaction of the method of the
invention is carried out on the surface of a solid
support. As known in the art, the solid support may
be any support which does not interfere with the
assay. Exemplary of solid supports which may be used
are glass and polymeric materials, such as poly-
ethylene, polystyrene and the like. Such supports
may be Eabricated into any suitable shape, such as
sheets, plates, wells, or, preferably, tubes. In the

- ~2537~8
P-849
most preferred embodiment of the invention, the
immunological reaction is carried out on the inside
walls and bottom of a tube, preferably a plastic tube
with one closed end.
5An anti-analyte is attached to the surface of
the solid support. The anti-analyte may be an
antigen or an antibody which reacts specifically with
- the analyte, or it may be any appropriate analogue
thereof which reacts specifically with the analyte.
Attachment of the anti-analyte to the solid support
may be carried out by any conventional procedure,
such as, for example, absorption or covalent bonding.
These procedures are well known in the art, and no
further details in these respects are deemed neces-
sary for a complete understanding of the invention~
The quantity of anti-analyte to be attached to
the solid support depends on the type of assay to be
carried out. In a competitive immunoassay as will
first be described herein, a limited amount of
anti-analyte is attached, whereby insuficient
binding sites are available and the analyte and a
tracer for the analyte, described below, compete or
the available sites. In a sandwich assay, as will
subsequently be described, excess anti-analyte is
attached whereby essentially all analyte is bound to
the anti-analyte.
In a competitive assay in accordance with the
method of the invention, the anti-analyte attached to
the solid support is contacted with an unknown
quantity o~ analyte in a fluid, and the assay medium

~ 537~ P-849
is incubated as described below to induce an im-
munological reaction between the analyte and anti-
analyte. A tracer for the analyte is then added, and
a subsequent incubation is carried out so that the
assay medium contains free analyte, free tracer,
bound analyte and bound tracer. Alternatively and
preferably, the analyte and tracer are added simul-
taneously and a single incubation is carried out.
Analyte and tracer bound to the anti-analyte on
the solid support are hereinafter referred to as the
bound fraction, and analyte and tracer which do not
bind to the anti-analyte are hereinafter refer~ed to
as the free fraction.
The tracer provides a means to follow the course
of the immunologlcal reaction, and, in a competitive
assay, preferably consists of a known quantity of the
analyte or appropriate analogue thereof coupled to a
label. The label may be any substance which absorbs
and emits light and which may be coupled to the
analyte. The pre~erred label emits light of long
decay time, most preferably long decay fluorescence
emission, which allows detection of the bound tracer
without any substantial interference from other light
emitting materials in the assay system~ The most
preferred labels absorb excitation light o~ wave-
length about 280 to 375 nm, emit fluorescence of
wavelength about 580 to 630 nm, and have a Stoke's
shift of from about 200 to 250 nm. The decay time of
the fluorescence emission of the most preferred
labels is from about 0.5 to 1.0 ms.
~ong decay time fluorescent labels useful in

i~ z~;37~
P-849
--1 0--
accordance with the method of the invention are
pyrene derivatives and, preferably, the lanthanide
chelates. The latter class of labels consists of a
lanthanide ion, such as an ion of europium or terbium
chelated with an organic ligand, as, for example, a
~-diketone. Exemplary of ~-diketones which can be
used are benzoylacetone, dibenzoylmethane, thenoyl-
trifluoroacetone, benzoyltrifluoroacetone, naphthoyl-
trifluoroacetone, acetylacetone, trifluoroacetylace-
tone, hexafluoroacetylacetone, and the like. Chela-
tion of the ~-diketone with the lanthanide ion is
routinely carried out by incubating the reagents for
an appropriate time. The quantity of lanthanide
chelate to be used in preparation of the tracer
depends on the type of assay to be carried out and
the quantity of analyte in the fluid, and is well
known to those of ordinary skill in the art.
The lanthanide chelate label may be coupled
directly to the analyte by conventional means to
produce the tracer. Alternatively and preferably,
the label is incorporated into a particle, and the
particle is attached to the analyte to give the
tracer. The particle may be a polymeric particle,
such as a bead. Any polymer may be used which is
capable of incorporation of the label and attachment
to the analyte. The preEerred polymers are essen-
tially transparent to both the excitation light and
the fluorescence emission, and do not enter into any
substantial number of non-specific surEace reactions
with proteins other than the anaIyte, as, ~or exam-
ple, other proteins in serum. ~ particularly pre-
Eerred polymer or incorporation of the label is a
poly~r~lake, as, Eor @xample, polymethylmethacrylate

~5379~
P-849
The label is incorporated into the particle by
conventional methods. For example, a polymeric
particle containing the label may be prepared by
emulsion polymerization of a monomer in a solution
containing the label. Likewise, the particle is
attached to the analyte by conventional means,
preferably by covalent coupling of appropriate
functional groups on the analyte and on the surface
of the particle. The conventional methods for
incorporation of the label into the particle and
attachment of the particle to the analyte are well
known and are deemed to be within the purview of
those skilled in the art, and no further details with
regard to those elements are necessary for a complete
understanding of the invention.
The assay medium containing the supported
anti-analyte, the fluid containing the analyte, and
the tracer may be incubated at any temperature and
for any length of time suitable to facilitate the
immunological reaction and thereby provide the
aforementioned bound and free fractions. The
incubation may be carried out at a temperature from
about 0 to 50C, preferably from about 30~to 40C,
and ma~, but need not, result in equilibrium between
these fractions.
A light absorbing material is added to the assay
system either before or after the immunological
reaction, and may be any material which has an
absorption band which overlaps the absorption band of
the tracer and which does not interfere with the
immunological reaction~ Suitable absorbing materials
are exemplified by, but not limited to, stilbenes,

~2 S 3q 9~ P-849
-12-
benzoxazoles, naphthalenes and derivatives thereof.
A preferre~ yroup is the arylaminonaphthalene sul-
fonic acids, as, for example, 2-tp-anisidinyl)
naphthalene-6-sulfonic acid or l-anilinononaphtha-
lene-8-sulfonic acid (1,8-ANS). The concentration of
absorbing material in the assay medium may be from
about 10 2 to 10 6M, preferably from about 10 3
to 10 4M.
Bound tracer is detected by applying excitation
light and measuring light emission from the label in
the presence of the light absorbing material. The
excitation light preferably has a wavelength within
the absorption range of the label used. When the
label is a lanthanide chelate, the excitation
light preferably has a wavelength of from about 280
to 375 nm, most preferably about 343 nm and is
discontinuous, i.e., pulses of light alternate with
periods when the light source is off. The light
pulses may be from about 0.1 to 10 ~s, preferably
about 3 ~s in duration. The periods when the light
source is off may be from about 0.1 to 2.0 ms,
preferably ~bout 0.9 ms.
Light emission is preerably measured by time-
gating after a delay o~ about 0.1 to 0.5 ms, prefer-
ably about 0.5 ms from completion of a pulse. Thewavelength of the light emission depends on the label
used. When the label is a lanthanide ~helate, the
emission wavelength generally is from about 580 to
630 nm. Most preEerably, emission is measured at
a wavelength of about 614 nm.
Measurement of light emission by time-gating in
accordance with the preferred method of the invention

537~ P-849
--1 3--
may be carried out in a conventional spectrophotome-
ter, as, for example, a Spex L-111 fluorimeter (SPEX
Industries, Inc., Edison, N.J.) equipped with a gated
photon detector. Emission may be measured at any
angle to the beam of excitation light. Prefera~ly,
emission is measured at an angle of about 2-20
degrees from the beam of excitation light.
The light absorbing material in the fluid phase
of the assay system absorbs all excitation and~or
emission light which passes through the fluid phase
and thereby effectively prevents detection of emis-
sion from free tracer. On the other hand, bound
tracer absorbs and subsequently emits detectable
light which has not passed through the fluid phase.
The method and components of the invention are
depicted in Figure 1 wherein assay system 10 includes
a preferably polystyrene tube 13 having an open end
11 and a closed end 12~ Tube 13 contains a bound
fraction 15 and fluid phase 17. Bound fraction 15
includes anti-analyte 19 attached to the inside walls
of tube 13 and bound analyte ~1 and bound tracer 23.
Bound tracer 23 comprises bound analyte 21 having
attached polymeric par~cle 25 with incorporated
fluorescent dye label 27. Fluid phase 17 includes
free analyte 21a, free tracer 23a and light absorbing
material 29~
Excitation light, schematically illustrated by
reference line 31, passes through tube 13 and is
absorbed by material 29, or it may pass through tube
13 and be absorbed by bound tracer 23 or free tracer
23a~ Fluorescence emission from bound tracer 23
~Trade M~rk
,.
,,

~7 g~ P-849
-14-
includes emission 33a into fluid phase 17 where it is
absorbed by material 29, and emission 33b outwardly
through tube 13 without passing through fluid phase
17 where it is detected by fluorimeter 35. Emission
33c from free tracer 23a into fluid phase 17 is
absorbed by material 29.
Excitation light reflected from the solid
support does not interfere with measurement of
emission from bound tracer because emission is
measured when the light source is off. Short decay
time background light emission associated with
serum or other fluorescent materials in the assay
medium, including that associated with the solid
support itself, is essentially eliminated by time-
lS resolved measurement of emission. Thus, in accor-
dance with the method of the invention, the only
light emission detected is ~rom the tracer bound to
the surface of the solid support.
In a competitive assay as hereinabove described,
the magnitude of the light emission is directly pro-
portional to the quantity of bound tracer and there-
fore is inversely proportional to the ~uantity of
analyte present in the fluid. The concentration of
the analyte in the fluid may be determined by com-
paring the magnitude of light emission measured uponassay of the analyte with the emission measured upon
assay of a range of known ~uantities of the analyte
assayed under essentially identical conditions.
~he method o the invention may be adapted to a
solid phase sandwich assay. Thi~ type of assay is
particularly useul ~or assay of a macromolecular

-` ~2S37~
P-84 9
analyte, as, for example, a protein. Any modifica-
tion of solid phase sandwich assay may be used. For
example, the anti-analyte may be attached to the
solid support in sufficient quantity to bind essen-
tially all of the analyte through a first determinanton the analyte~ The supported anti-analyte may be
incubated with the analyte, the light absorbing
material and a tracer wherein the tracer comprises a
labeled ligand specific for a second determinant
on the analyte. The ligand may be an antigen, an
antibody or a bound antigen-antibody complex.
The preferred label and light absorbing material
and the preferred method for excitation and detection
of emission may be as described above for the compe-
titive assay. However, in the sandwich assay of thisembodiment of the invention, the concentration of the
analyte present in the fluid is directly proportional
to the magnitude of light emission.
In accordance with another aspect of the inven~
tion, there is provided a reagent kit or package of
materials for accomplishing an assay for an analyte
in accordance with the method oE the invention. The
Xit may include a solid support having attached
thereto an anti-analyte specific to the analyter a
light absorbing material, and a tracer for the
analyte having attached theret~ a label capable of
absorbing excitation light and emitting detectable
light. The kit may also include standards for the
analyte, as, for example, one or more analyte samples
of known concentration, or it may include other
reagents, such as other labeled or unlabeled specific

~ 53~79~
P-849
-16-
antigens, antibodies or complexes thereof useful
in carrying out the assay. The components of the kit
may be supplied in separate containers, as, for
example, vials, or two or more of the components may
be combined in a single container.
The following examples of a model system and an
assay for digoxin are provided to further describe
the invention, but are not intended in any way to be
limitative of the invention.
EXAMPLE I
Polymethylmethacrylate beads of about 150 nm
containing about 1~ naphthoyltrifluoroacetone-euro-
pium chelate (NTFA3EU) were suspended in water and
sprayed onto the surface o polystyrene cuvettes.
The cuvettes were dried overnight at ambient tempera-
ture whereby the beads adhered to the surface
and were not removed by washing with water. The
cuvettes thus coated were used to represent the bound
fraction of a TR-FIA, i.e., the solid support with
attached anti-analyte and tracer.
An aqueous suspension of about 1 x 104 beads
per ml was added to all cuvettes to represent the
fluid phase of a TR FIA containing ~ree tracer.
Aqueous solutions of 1, 8-ANS o the concentra-
tions given in Table I were added to the cuvettes.
Qne control cuvette received water only.
Using a Spex L-lll fluorimeter equipped with a
gated photon detector, pulsed exci~ation light at 343
nm was applied at a right angle to the cuvettes.

37~
P-8~9
Fluorescence emission at 614 nm was measured, after a
delay of 0.5 ms, at angles of 11 and 90 to the beam
of excitation light. The results are given in Table
I and show the effect of 1,8-ANS concentration on the
fluorescence emission of the suspended beads.
TABLE I
Concentration of 1,8-ANS Number of Photons Detected
-
(moles per liter) 11 90
0 31,500 32,300
1 10-2 1,300 45
1 x 10~3 1 300 876
1 x 10 4 27,200 31,400
It is seen that 1,8-ANS having a concentration of 1 x
10 3M eliminated all emission except that at-
tributed to the bound beads.
EXAMPLE II
Two groups of three cuvettes each were coated,
as described in Example I, with two different concen-
trations of beads. One cuvette in each group re-
ceived water and represented the bound fraction of a
TR-FIA. A second cuvette in each group received a
suspension of the beads and represented the bound and
free fractions of a TR-FIA. The third cuvette in
each ~roup received a suspension of the beads
containing 5 x 10 3M 1,8-ANS.
Excitation and measurement of fluorescence
emi~ion at 11 were carrled out as described in
Example I. Th~ results are given in Table II.

2~79~
P-849
-18-
TABLE II
Number of Photons Detected
Cuvette 1 Cuvette 2
Coated Cuvette + Water 2,300 40~000
tBound Fraction)
Coated Cuvette + Suspended Beads 32,400 71,000
(Bound and free fractions)
Coated Cuvette + Suspended Beads + 2,700 38,000
S x 10 3M 1,8-ANS (Bound and
free fractions and light
absorbing material)
It is seen that, in the presence of the ab-
sorbing material, the beads on the cuvette surface
(bound fraction) were selectively excited and their
fluorescence emission detected in the presence of a
large excess of beads in suspension (free fraction).
EXAMPLE III
A. Preparation of the Fluorescent Polymer Particles
-
A polymer bead consisting of a 92:6:2 ratio of
butyl methacrylate:glycidyl methacrylate:sul~oethyl
methacrylate containing 1% NTFA3EU was prepared in
the Eollowing manner. Bis methylene acrylamide ~.05
g) and polyethylene oxide (0~1 g) were dissolved in
deionized water (25 ml) and acetone (4 ml). A second

' P-84~
--1 9--
solution was prepared which contained butyl methacry-
late (0.78 ml), ~ulfoethyl methacrylate ~0.2 g),
glycidyl methacrylate (0.5 ml) and NTFA3Eu (25
mg). The two solutions were mixed together and the
pH ad~usted to 5~5 with 1 N NaO~. After stirring
well under N2, the mixture was irradiated for 12 hr
at 7.05 ~r~hr, The white emulsion was spun in a
eentrifuge at successively increased speeds. T,he
pellet which was collected at 30,000 rpm was washed
three times with 0.1~ polyoxyethylenesorbitan mono-
laurate ~Tween 20J in phosphate buffered saline
(PBS-.'01 M mixture of mono and di sodium phosphate in
0.15 M NaCl). The pellet was ultimately suspended in
a 10% solution of 1,3-diaminopropane in which the pH
was adjusted to 10 with 1 N HCl. The suspension was
stirred overnight and then washed three times and
suspended in 30 ml of PBS~
B. Preparation of the BSA-Digox:in Particle Conjugate
A sample (1.0 ml~ of the particle suspension
described in A was activated by the addition of
glutaraldehyde at a final concentration of ~. A 4
hr incubation was followed by three washings in PsS.
To 1 ml of the activated beads was added 5 mg of a
bovine serum albumin (BS~)-Digoxin conjugate. The
mixture was stirred overnight at room tampera-
ture. The beads were washed three times, suspended
in 25 ml of PBS, and stored at 4C.
C. _ atin~ of Polystyrene Cuvettes with ~abbi~
Anti-Di~oxin Immunoglobulin
A two thousandQld dilutLon oE rabbit anti-
~igoxin XmmunoglobulLn was made into 0.1 M carbonate
*Trade Mark

~L25~79~
P-849
-20-
buffer, pH 9.5. This solution was pipetted to the 3
ml level of the cuvettes~ After incubation at room
temperature for 4 hr, the cuvettes were aspirated and
washed successively with a 2% BSA solution in PBS and
finally in PBS. The cuvettes were dried and stored
at 4C
D Determination of a Standard Curve for Digoxin in
.
Phosphate Buffer
Duplicate dilution series of Digoxin were made
in PBS containing BSA (2%) and Tween 20 (0.5~) in the
range of 1-10 ,000 ng/ml and then 3 ml each of these
solutions and of blank PBS were pipetted into the
cuvettes which had previously been coated as de-
scribed in C. To each of these cuvettes was added
30 ~l of the BSA-Digoxin particle conjugate prepared
in section B~ The cuvettes were incubated at 37C
for 45 min. To each of the cuvettes was added 0.1 M
1,8-ANS (30 ~l) and fluorescence emission at 614 nm
was measured after a delay of 0.5 ms at an angle of
11 to the beam of excitation li.ght. The results are
given in Table III and Figure 2
_ABLE III
Diqoxin Concentration (n~/ml) Intensity (photons)
0 8700
1 87Q0
25 10 ~8200
100 ~ 7000
1000 61 00
10000 4500

'` ~253~9~
P-849
--2 1--
EXAMPLE IV
A. Preparation of Anti-HCG Immuno~lobulin Particle
Con~uyate
: A sample (1.0 ml) of the particle suspension
described in Example IIIA was activated by the
addition of glutaraldehyde at a final concentration
of 1~. A 4 hr incubation was followed by three
washings in PBS. To 1 ml of the activated beads were
added 50 ~1 of a 1 mg/ml solution in PBS of a mono-
clonal antibody designated HCG-13 raised in the
conventional way against HCG. The mixture was
stirred overnight at room temperature. The beads
were washed three times, suspended in 25 ml of PBS,
and stored at 4C.
B. Coating of Polystyrene Cuvettes with Monoclonal
Anti-HCG-4 Immuno~lobulin
A five thousandfold dilution of a second mono-
clonal antibody raised against HCG designated HCG-4,
was made into 0.1 M carbonate buffer, pH 9.5. This
solution was pipetted to the 3 ml level of the
cuvettes. After incubation at room temperature for 4
hrr the cuvettes were aspirated and washed succes-
sively with a 2~ BSA solution in PBS and finally in
PBS. The cuvettes were dried and stored at 4C.
C ~etermination of a Standard Curve for HCG in
Phosphate Buffer
Duplicate dilution series of~ HCG were made in
PBS of 10 ~old concentration in the range oE 0.15 -
1.~x105 mIU/ml. ~he~e solutions and a blank P~S

P-849
-22-
were pipetted into the cuvettes which had previously
been coated as described in B. After a 1 hr incuba-
tion at 37C, the microbeads (50 ~l) described in
A were added, and incubation was continued for
another hr. To each of the cuvettes was added 0.1 M
1,8-ANS (30 ~l), and fluorescence emission at 614 nm
was measured after a delay of 0.5 ms at an angle of
11~ to the beam of excitation light. The results are
given in Table IV and Figure 3.
TABLE IV
HCG Concentration (mIU/ml) Intensity (photons)
O ' 1, 000
0.15 1,380
1,750
1,500 2,000
150,000 2,600
Thus, in accordance with the invention, a method
for solid phase ~luoroimmunoassay includes addition
of a light absorbing material to the fluid phase of
the assay system. The light absorbing material
absorbs all excitation and/or emitted light except
that absorbed by and emitted from bound tracer,
whereby the emission from the bound tracer can be
detected and measured in the presence of a large
excess of Eree tracer. Separation of the bound and
free fractions is thus avoided and the simplicity and
convenience of a homogeneous assay is gained. By
measuring light emission from the bound tracer usin~

~:537~
P 849
-23-
time resolution, in~erference from reflected excita-
tion light and from light scattering and background
emission can be minimi~ed whereby higher assay
sensitivity can be achieved. The method is easily
adaptable to all modifications of solid phase compe-
titive and sandwich type assay systems. The inven-
tion includes a kit of assay materials which can be
used for either manual or automated assay.

Representative Drawing

Sorry, the representative drawing for patent document number 1253798 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Expired (old Act Patent) latest possible expiry date 2006-05-09
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Grant by Issuance 1989-05-09

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
BECTON, DICKINSON AND COMPANY
Past Owners on Record
DANIEL B. WAGNER
ROBERT A. BAFFI
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column (Temporarily unavailable). To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.

({010=All Documents, 020=As Filed, 030=As Open to Public Inspection, 040=At Issuance, 050=Examination, 060=Incoming Correspondence, 070=Miscellaneous, 080=Outgoing Correspondence, 090=Payment})


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Abstract 1993-09-06 1 26
Claims 1993-09-06 7 207
Drawings 1993-09-06 3 30
Descriptions 1993-09-06 24 787